Mylan NV’s independent Dutch foundation, named Lazard as its financial adviser, a step that could help it play a more active role as fellow drugmaker Teva Pharmaceutical Industries Ltd. pursues a takeover.
The foundation, known as a stichting, is also working with Roland Berger Strategy Consultants and with law firms Spinath & Wakkie and Skadden, Arps, Slate, Meagher & Flom, according to a page added to its website Thursday. Under Dutch law, the foundation can exercise an option to help prevent takeovers.
Mylan has rejected Teva’s $40.1 billion offer and instead is trying to buy drugmaker Perrigo Co., which so far has declined its advances. The foundation said last week it has concerns about Teva’s purchases of Mylan shares on the open market, where it has built up a 3.3 percent stake in its takeover target.
The foundation could only delay an acquisition by Teva by a few months at most, rather than prompting the Israeli drugmaker to walk away altogether, a person familiar with Teva’s thinking said in April.
Spokesmen for Mylan and Teva declined to comment.